Palisade Bio (PALI) EBITDA Margin (2011 - 2023)

Palisade Bio's (PALI) quarterly EBITDA Margin came in at 1011.6% in Q1 2023, up 99.22% on a QoQ basis from 129800.0% in Q4 2020.

Palisade Bio (PALI) EBITDA Margin (2011 - 2023) Analysis & Trends

Palisade Bio (PALI) has 11 years of EBITDA Margin data on file, last reported at 1011.6% in Q1 2023.

On a quarterly basis, EBITDA Margin changed N/A year-over-year to 1011.6% in Q1 2023; TTM through Dec 2023 was 5228.0%, a N/A change from a year earlier, with the FY2023 full-year figure at 5228.0%, changed N/A from the prior year.
EBITDA Margin for Q1 2023 stood at 1011.6%, up from 129800.0% in the prior quarter.
Over the last five years, EBITDA Margin for PALI reached as high as 1011.6% in Q1 2023 and fell as low as 129800.0% in Q4 2020.
Historically, EBITDA Margin has averaged 66998.9% across 3 years, with a median of 73640.0% in 2020.
On a YoY basis, EBITDA Margin climbed as much as 6519841 bps in 2020 and fell as far as 4933824 bps in 2020.
Year by year, EBITDA Margin stood at 85302.92% in 2019, then sank by 52 bps to 129800.0% in 2020, then soared by 99 bps to 1011.6% in 2023.
Per Business Quant data, the three most recent EBITDA Margin figures were 1011.6% in Q1 2023, 129800.0% in Q4 2020, and 72640.0% in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Palisade Bio	985.76	-132.63 Mn	-	-

Download Data